Navigation Links
BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Date:1/30/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting MS. The lead clinical development program for dirucotide is for secondary progressive MS where it is being evaluated in two ongoing phase III trials in the United States, Canada and Europe, with results from the Canadian and European MAESTRO-01 trial expected in the second half of 2009.

The results of the MINDSET-01 study showed that dirucotide did not meet its primary endpoint, annualized relapse rate or associated secondary MRI endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) score. The EDSS is a method of quantifying disability in MS, while the MSFC evaluates additional functional parameters. Measuring changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III secondary progressive MS trials.

The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events.

BioMS and its partner Eli Lilly & Company (Lilly) will continue to analyze the results of this exploratory phase II trial. Under the terms of the licensing agreement with Lilly, no milestone payment was associated with this trial.

"We are encouraged that dirucotide has demonstrated an effect on certain clinical measures of disease progression, this time in the earlier form of the disease," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was developed as a potential treatment f
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical recognized at Scrip Awards 2008
2. BioMS Medical Announces Third Quarter 2008 Results
3. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
7. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
8. BioMS Medical to present at UBS Global Life Sciences Conference
9. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 According to ... "Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, ... - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - ... 2013 - 2019," the global electrodes market for medical ... and is estimated to reach a market worth USD ...
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 ... an Irys™System by BGI , the ... enable comprehensive exploration of human structural variation (SV) and ... interest, including those where no reference exists. In addition, ... methods for multiplexing on the Irys System, enabling significantly ...
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... wave of automation across the U.S., increasing unemployment, ... middle class. It is a Catch 22—we ... internationally, but this means fewer jobs,” says economist ... the just-released Pollina Corporate Top 10 Pro-Business States ...
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
Breaking Biology Technology:Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3
... CRANBURY, N.J., March 9, 2011 Palatin Technologies, Inc. (NYSE ... presenting at the ROTH 23rd Annual OC Growth Stock Conference ...  The conference will be held at the Ritz Carlton Laguna ... Ph.D., President and Chief Executive Officer of Palatin Technologies, will ...
... Leading events organiser UBM Live and its sister ... of the anticipated content and new developments taking place at ... event, being held from 18-20 April, 2011 at the Big ... surrounding CPhI Japan includes P-MEC Japan, which covers Pharma machinery ...
... March 8, 2011 In addition to reliable high ... expertise with the development of the Reagent Agent(SM) - ... solution for delivery of any nucleic acid into any ... Search results are based on extensive in-house transfection and ...
Cached Biology Technology:UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 4Reagent Agent(SM) Transfection Cell Line Database From The Transfection Experts 2
(Date:7/30/2014)... 2014 ResearchMoz presents this ... Systems Market 2014-2024   Business Strategies, Industry Trends, and ... Market 2014-2024" offers the reader detailed analysis of ... ten years, alongside potential market opportunities to enter ... To view the table of contents for ...
(Date:7/30/2014)... shrinking ranges and a changing climate threaten some ... plants, and so conservationists establish seed collections to ... in hopes of preserving some genetic diversity., For ... simple models that offer a one-size-fits-all approach for ... saving 50 seed samples regardless of species, pollination ...
(Date:7/30/2014)... humans figured out how to create colors, nature had ... wings of many different hues, for example. Now scientists ... environmentally friendly way to make colored plastics. Their paper ... of materials rather than dyes, to produce color ... , N. Asger Mortensen, Anders Kristensen and colleagues point ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Saving seeds the right way can save the world's plants 2
... published in the January 2006 issue of Nature Biotechnology, ... Sloan-Kettering Cancer Center have devised a novel strategy that ... genetically reverse sickle cell disease (SCD) in human cells. ... to genetically correct this debilitating blood disease using RNA ...
... their fertile years, biologists have searched for evolutionary clues ... natural selection play in the evolution of the postreproductive ... the twilight years, postreproductive females should contribute to the ... the "grandmother effect." Though many mammals, including lions and ...
... Sheffield has shown that major oil spills and a changing ... British sea birds than was previously thought. , A ... Animal and Plant Sciences at the University of Sheffield, shows ... mortality rate of adult guillemots in Britain, even though the ...
Cached Biology News:Sickle cell disease corrected in human models using stem cell-based gene therapy 2Getting an evolutionary handle on life after reproduction 2Oil spills and climate change double the mortality rate of British seabirds 2
... six short years since publication of the ... widely acclaimed Protein Protocols Handbook, there have ... biochemistry. In recognition of the level of ... evolution of new methodologies directed to study ...
... Pan-Caspase In Situ Assay Kit, Fluorescein is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... Pan-Caspase In Situ Assay Kit is a ... in cells undergoing apoptosis. The kit is ... in diagnostic or therapeutic procedures. CHEMICON®s CaspaTag™ ... novel approach to detect active caspases. The ...
...
Biology Products: